Healthcare Industry News: spinal cord stimulation
News Release - February 15, 2019
Nevro Files Lawsuit for Patent Infringement Against Stimwave in the U.S.
REDWOOD CITY, Calif., Feb. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has filed a lawsuit for patent infringement against Stimwave Technologies, Inc. The lawsuit, filed in the United States District Court for the District of Delaware on February 14, 2019, asserts that Stimwave is infringing Nevro's patents covering inventions relating to Nevro's groundbreaking Senza® system and HF10® therapy. The lawsuit seeks preliminary and permanent injunctive relief against further infringement as well as damages and attorney's fees."Nevro was founded in 2006 to develop meaningful advances in the treatment of chronic pain to improve patients' lives," said Rami Elghandour, President and CEO of Nevro. "Intellectual property is the basis for innovation in health sciences given the long development timelines, investment, and risk required to bring meaningful advances to market. We are committed to ensuring continued innovation in health sciences by protecting our intellectual property."
Documents relating to the lawsuit will be available via registration at the court's website, www.ded.uscourts.gov.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Source: Nevro
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
